BIVI Research Note — Evidence Before the Headline
BioViespeed fell to $20.06, while negative gross margin and a larger share count leave the recovery thesis dependent on fresh factory evidence.
CAMS Research Desk
BIVI Deep Coverage Review — Analysis as of July 31, 2026
BioViespeed’s lower share price does not repair negative gross margin, weak utilization or dilution risk ahead of the next operating update.
Weekly Market Outlook — Week of August 3, 2026: The Post-Fed Repair Job, and the Participation It Still Owes
SPY reclaimed its 50-day average, but only 38% of the active watchlist clears the same line. This week tests whether participation catches up.
VICI Research Note — Guidance Rises, Shares Fall
VICI raised guidance as its shares fell 3.02%; rates, funding costs and concentrated tenant exposure now put the valuation discount to a harder test.
VICI Deep Coverage Review — Analysis as of July 31, 2026
VICI raised 2026 guidance, but tenant concentration, a 4.66% Treasury yield and the marginal cost of growth capital still define the valuation discount.
Market Structure: Rates Rise as Leadership Rotates — August 1, 2026
The S&P 500 is holding its intermediate trend, but Nasdaq weakness, rising rates, and 38% watchlist breadth keep the regime mixed.
WULF Research Note — Clearances Do Not Close the Gap
WULF’s clearances matter, but the cash bridge to a second-half 2027 revenue start remains the central question.
WULF Deep Coverage Review — Analysis as of July 31, 2026
WULF’s new clearances reduce development risk, while the 2027 revenue start leaves financing and operating proof unresolved.
JQC Research Note — The Yield Needs Proof
JQC’s floating-rate loan income remains substantial, while two distribution reductions and limited credit detail keep durability unresolved.
JQC Deep Coverage Review — Analysis as of July 31, 2026
JQC offers floating-rate loan income at an estimated discount, but repeated distribution reductions keep payout durability and credit quality unresolved.